Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 29;10(12):e042484.
doi: 10.1136/bmjopen-2020-042484.

Burden of diabetic macular oedema in patients receiving antivascular endothelial growth factor therapy in South Korea: a healthcare resource use and cost analysis

Ha-Lim Jeon  1 , Hyesung Lee  1 , Dongwon Yoon  1 , Yeonkyung Lee  2 , Jae Hui Kim  3 , Donghyun Jee  4 , Ju-Young Shin  5
Affiliations

Burden of diabetic macular oedema in patients receiving antivascular endothelial growth factor therapy in South Korea: a healthcare resource use and cost analysis

Ha-Lim Jeon et al. BMJ Open. .

Abstract

Objective: To examine healthcare resource utilisation (HRU) and direct medical costs for patients with diabetic macular oedema (DME) treated with antivascular endothelial growth factor (anti-VEGF) in Korea by comparing with those for (1) patients with diabetes mellitus (DM) without retinopathy and (2) patients with neovascular age-related macular degeneration (nAMD) treated with anti-VEGF.

Design: Retrospective cohort study.

Setting: The Korean National Health Insurance (NHI) database from 1 January 2014 to 31 December 2016.

Participants: We identified 1398 patients older than 30 years of age who received anti-VEGF treatment for DME in 2015 after excluding patients who had a diagnosis of nAMD in 2015 and any cancer in the preceding year.

Main outcome measures: One-year healthcare resource use and direct medical costs of patients with DME treated with anti-VEGF.

Results: In total, 1398 patients with DME receiving anti-VEGF, 12 813 patients with DM without retinopathy and 12 222 patients with nAMD receiving anti-VEGF were identified. Hospital admissions and outpatient visits were highest in patients with DME, while the number of licensed anti-VEGF injections in those with DME was about half that of those with nAMD (2.1 vs 3.9 per patient per year). Mean 1-year medical costs were also higher in patients with DME (US$6723) than in those with DM without retinopathy (US$2687) and nAMD (US$4980). In a multivariable analysis with matched cohorts, DME was associated with 66% higher medical costs for comorbid diseases (adjusted OR (aOR), 1.66; 95% CI 1.45 to 1.90) and 50% lower anti-VEGF injections (aOR, 0.50; 95% CI 0.46 to 0.54) compared with nAMD.

Conclusions: The overall HRU and economic burden for DME treated with anti-VEGF were higher than for DM without retinopathy or for nAMD treated with anti-VEGF. Meanwhile, the lower number of licensed anti-VEGF injections compared with nAMD may reflect a potential lack of ophthalmological treatment for DME supported by the NHI in Korea.

Keywords: diabetic retinopathy; public health; vitreoretinal.

PubMed Disclaimer

Conflict of interest statement

Competing interests: J-YS reported receiving grants from the Ministry of Food and Drug Safety, the Ministry of Health and Welfare, the National Research Foundation of Korea, and Government-wide R&D Fund for infectious disease research; and grants from pharmaceutical companies including Amgen, Pfizer, Hoffmann-La Roche, Dong-A ST and Yungjin, outside the submitted work. H-LJ, HL, DY and J-YS reported grants from Bayer, the National Research Foundation of Korea, and Government-wide R&D Fund for infectious disease research. YL is an employee of Bayer Korea. JHK is a consultant for Bayer Korea in this study. DJ has no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Study scheme and selection of patients with DME treated with anti-VEGF (A), DM without retinopathy (B), and nAMD treated with anti-VEGF (C). Anti-VEGF, antivascular endothelial growth factor; DM, diabetes mellitus; DME, diabetic macular oedema; nAMD, neovascular age-related macular degeneration.
See this image and copyright information in PMC

References

    1. Chen E, Looman M, Laouri M, et al. . Burden of illness of diabetic macular edema: literature review. Curr Med Res Opin 2010;26:1587–97. 10.1185/03007995.2010.482503 - DOI - PubMed
    1. Shea AM, Curtis LH, Hammill BG, et al. . Resource use and costs associated with diabetic macular edema in elderly persons. Arch Ophthalmol 2008;126:1748–54. 10.1001/archopht.126.12.1748 - DOI - PMC - PubMed
    1. Hariprasad SM, Mieler WF, Grassi M, et al. . Vision-related quality of life in patients with diabetic macular oedema. Br J Ophthalmol 2008;92:89–92. 10.1136/bjo.2007.122416 - DOI - PubMed
    1. Klein R, Klein BE, Moss SE, et al. . The Wisconsin epidemiologic study of diabetic retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 1995;102:7–16. 10.1016/s0161-6420(95)31052-4 - DOI - PubMed
    1. Klein RKB, Moss SE. The epidemiology of ocular problems in diabetes mellitus.: Boston. MA: Blackwell Scientific Publications, 1991: 1–51.

Publication types

MeSH terms

Substances